Metabolic Staging vs TNM Staging: Does Insulin Resistance Predict Cancer Outcomes Beyond Tumor Size? (2026)
Abstract
The Tumor–Node–Metastasis (TNM) classification system, standardized by the American Joint Committee on Cancer (AJCC), remains the global foundation for cancer prognosis and treatment stratification. TNM staging focuses exclusively on tumor burden and anatomical spread. However, mounting evidence suggests that host metabolic factors — particularly insulin resistance and hyperinsulinemia — influence cancer progression, recurrence, and survival independently of tumor stage. This review synthesizes mechanistic, epidemiologic, and interventional evidence linking insulin resistance to oncologic outcomes across multiple malignancies. We examine whether metabolic markers such as fasting insulin, HOMA-IR, and the triglyceride-glucose (TyG) index provide prognostic information beyond TNM classification. While TNM remains indispensable, emerging data support a dual-axis model incorporating tumor burden and metabolic host status. Further prospective trials are required to determine whether metabolic correction modifies survival independently of anatomical stage..png)
1. Introduction
For decades, cancer prognosis has relied on anatomical classification. The TNM system, overseen globally by the American Joint Committee on Cancer and the Union for International Cancer Control, categorizes malignancies based on:
Tumor size and local invasion (T)
Regional lymph node involvement (N)
Distant metastasis (M)
TNM staging guides:
Surgical decision-making
Adjuvant therapy
Clinical trial eligibility
Survival prediction models
Yet clinical heterogeneity persists within stage categories. Two patients with identical Stage II colorectal cancer may experience markedly different outcomes. This variability has traditionally been attributed to molecular heterogeneity. Increasingly, however, systemic metabolic state is emerging as a potential modifier of tumor biology.
The concept of metabolic influence in cancer traces back to Otto Warburg’s early 20th-century observations of altered tumor glucose metabolism (1). Contemporary metabolic oncology researchers, including Thomas Seyfried, have expanded this paradigm to consider systemic metabolic environment as a contributor to tumor behavior (2).
The central question examined here is not whether metabolic markers replace TNM staging. Rather:
Do markers of insulin resistance provide independent prognostic information that refines risk beyond tumor size and spread?
2. Biological Rationale: Insulin as a Mitogenic Signal
2.1 Insulin and Cancer Cell Signaling
Insulin is not merely a metabolic hormone; it is a potent growth factor.
Hyperinsulinemia activates:
PI3K/Akt signaling
mTOR pathways
MAPK cascades
These pathways regulate:
Cell proliferation
Apoptosis suppression
Protein synthesis
Angiogenesis
Insulin also reduces hepatic production of insulin-like growth factor binding proteins, increasing bioavailable IGF-1, which further stimulates mitogenesis (3).
2.2 Insulin Resistance and Compensatory Hyperinsulinemia
Insulin resistance leads to compensatory hyperinsulinemia years before overt diabetes develops (4). Chronic hyperinsulinemia exposes tumors to persistent growth signaling independent of glucose availability.
In vitro studies demonstrate that insulin enhances proliferation in breast, colon, and prostate cancer cell lines (5).
2.3 mTOR and Metabolic Fertility
mTOR activation links nutrient availability with cellular growth. Persistent mTOR activation is observed in multiple malignancies and is stimulated by insulin signaling (6).
Thus, insulin resistance may create a systemic environment conducive to tumor progression.3. Evidence Linking Insulin Resistance to Cancer Incidence
Researchers from the University of Tokyo and Taichung Veterans General Hospital in Taiwan developed an artificial intelligence (AI) tool to predict insulin resistance.
The AI tool identified patients with insulin resistance and flagged higher risks of developing diabetes, heart disease, and cancer.
The association between insulin resistance and cancer incidence was strongest for uterine cancer, with a 134% increased risk.
4. Insulin Resistance and Cancer Prognosis
4.1 Breast Cancer
Goodwin et al. demonstrated that elevated fasting insulin levels were associated with increased recurrence and mortality in early-stage breast cancer independent of stage (9).
Similarly, HOMA-IR has been associated with worse disease-free survival in several cohorts (10).
4.2 Colorectal Cancer
Patients with metabolic syndrome have demonstrated increased recurrence rates after curative resection for colorectal cancer (11).
Hyperinsulinemia has been correlated with shorter overall survival (12).
4.3 Prostate Cancer
Higher insulin levels have been associated with aggressive prostate cancer and increased mortality risk (13).
4.4 Pancreatic Cancer
Pancreatic cancer presents bidirectional complexity: diabetes can be both risk factor and consequence. Nonetheless, pre-existing hyperinsulinemia is associated with increased incidence and possibly progression (14).
5. The TyG Index as a Practical Marker
The triglyceride-glucose (TyG) index has emerged as a simple surrogate for insulin resistance (15).
TyG = ln [fasting triglycerides (mg/dL) × fasting glucose (mg/dL)/2]
Studies have linked higher TyG scores to:
Increased overall mortality
Increased cancer incidence
Worse cardiovascular outcomes
Emerging oncology data suggest potential prognostic value in certain malignancies (16).
The appeal of TyG lies in its low cost and availability compared with fasting insulin assays.
6. Limitations of TNM Staging Alone
TNM staging:
Quantifies tumor burden
Does not account for systemic metabolic health
Does not measure immune competence
Does not reflect chronic inflammation
Within-stage variability suggests additional host modifiers influence outcomes.
Molecular subtyping (e.g., HER2, KRAS, MSI) improves precision but still focuses primarily on tumor intrinsic features.
Metabolic staging would introduce a host-level dimension.
7. Interventional Evidence: Does Modifying Insulin Sensitivity Affect Outcomes?
7.1 Exercise
Physical activity improves insulin sensitivity and is consistently associated with improved survival in breast and colon cancer (17).
Randomized lifestyle interventions demonstrate improvements in metabolic markers; long-term survival data remain evolving.
7.2 Metformin
Metformin lowers hepatic glucose production and improves insulin sensitivity.
Observational studies suggested reduced cancer incidence among diabetics using metformin (18). However, randomized trials in non-diabetic cancer patients have produced mixed results (19).
The discrepancy highlights the complexity of causality.
7.3 Weight Loss Interventions
Weight reduction improves insulin sensitivity, but whether intentional weight loss improves cancer-specific survival independent of stage remains under investigation.
7.4 GLP-1 Drugs
GLP-1 receptor agonists such as Semaglutide and Tirzepatide have transformed the treatment of obesity and type 2 diabetes. Do GLP-1 drugs reduce cancer risk — or is any apparent benefit simply a consequence of weight loss and improved metabolic health?More recent population studies (2023–2024) suggest neutral to modestly reduced obesity-related cancer incidence, but follow-up remains relatively short.
GLP-1 drugs represent a powerful metabolic intervention. Because obesity and hyperinsulinemia promote tumorigenesis, correcting these abnormalities may reduce cancer risk.
The emerging paradigm is not that GLP-1 drugs are anti-cancer therapies. It is that metabolic normalization may alter cancer biology — and GLP-1 drugs are one tool within that broader framework.8. The Obesity Paradox
Some studies report improved survival in overweight cancer patients — the so-called obesity paradox (20).
Possible explanations:
Reverse causality
Sarcopenia confounding
Treatment dosing bias
These findings reinforce that BMI alone is insufficient; insulin resistance may be a more biologically meaningful measure.
9. Toward a Dual-Axis Prognostic Model
A conceptual future model:
Axis 1: TNM tumor burden
Axis 2: Metabolic host status
Potential metabolic staging markers:
Fasting insulin
HOMA-IR
TyG index
Waist circumference
hs-CRP
Such a model could:
Identify high-risk patients within same stage
Inform adjunct therapy recommendations
Improve recurrence surveillance strategies
10. Research Gaps
Critical unknowns include:
Whether insulin-lowering interventions improve survival independent of stage
Whether insulin resistance predicts immunotherapy response
Whether metabolic staging improves prognostic accuracy beyond molecular profiling
Large-scale prospective trials incorporating metabolic markers at diagnosis are needed.
11. Clinical Implications
At present:
TNM remains foundational
Insulin resistance is not formally incorporated into staging
However, evidence supports:
Assessing metabolic health in oncology care.
Encouraging insulin-sensitizing lifestyle interventions.
Recognizing metabolic dysfunction as potential risk modifier.
This does not replace standard therapy. It contextualizes host biology.
12. Conclusion
TNM staging describes tumor anatomy.
Insulin resistance describes systemic growth signaling environment.
Current evidence suggests insulin resistance correlates with cancer incidence and prognosis across multiple malignancies. While not yet validated as a formal staging axis, metabolic status likely contributes to within-stage heterogeneity.
The future of precision oncology may incorporate both tumor-centric and host-centric models.
TNM versus metabolic staging is a false dichotomy.
The likely future is TNM plus metabolic context.
References
Warburg O. On the origin of cancer cells. Science. 1956;123:309-314.
Seyfried TN. Cancer as a metabolic disease. Wiley; 2012.
Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008;8(12):915-928. https://pubmed.ncbi.nlm.nih.gov/19029956/
Reaven GM. Banting lecture 1988: Role of insulin resistance. Diabetes. 1988;37:1595-1607.
Gallagher EJ, LeRoith D. Insulin and cancer. Endocrinol Metab Clin North Am. 2011;40(2):379-389.
Laplante M, Sabatini DM. mTOR signaling. Cell. 2012;149(2):274-293.
Giovannucci E et al. Diabetes and cancer. Diabetes Care. 2010;33(7):1674-1685.
Lauby-Secretan B et al. Body fatness and cancer. N Engl J Med. 2016;375:794-798.
Goodwin PJ et al. Fasting insulin and outcome in breast cancer. J Clin Oncol. 2002;20(1):42-51.
Duggan C et al. Insulin resistance and breast cancer survival. Cancer Epidemiol Biomarkers Prev. 2011.
Esposito K et al. Metabolic syndrome and colorectal cancer recurrence. Diabetes Care.
Ma J et al. C-peptide and colorectal cancer survival. J Clin Oncol. 2004.
Hsing AW et al. Insulin and prostate cancer. J Natl Cancer Inst.
Li D. Diabetes and pancreatic cancer. Clin Cancer Res. 2012.
Guerrero-Romero F et al. TyG index as surrogate for insulin resistance. Metab Syndr Relat Disord. 2010.
Recent TyG oncology prognostic studies (various cohorts 2021-2024).
Holmes MD et al. Physical activity and breast cancer survival. JAMA. 2005.
Evans JM et al. Metformin and reduced cancer risk. BMJ. 2005.
Goodwin PJ et al. Metformin in breast cancer RCT. J Clin Oncol. 2022.
Lennon H et al. Obesity paradox in cancer. Curr Oncol Rep. 2016. https://pubmed.ncbi.nlm.nih.gov/27475805/
Chavakis T. Immunometabolism: Where Immunology and Metabolism Meet. J Innate Immun 2022; 14: 1-3. 20211214. DOI: 10.1159/000521305.
Immunometabolism in lung cancer - The link between metabolism and immune response (ScienceDirect 2026)
Immunometabolism in cancer: basic mechanisms and new targeting strategy (Nature 2024)
The immunometabolic ecosystem in cancer (Nature 2023)
Machine learning-predicted insulin resistance is a risk factor for 12 types of cancer (Nature 2026)
Do GLP-1 Drugs Reduce Cancer Risk? A 2026 Evidence-Based Metabolic Oncology Review (Cancer Companion 2026)
Comments
Post a Comment